LRRC57

Across TCGA pan-cancer cohorts, LRRC57 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LRRC57 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher LRRC57 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC57 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

ESCA, UCEC, and LIHC are the cancer types where LRRC57 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.423	0.684	.010	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
COAD	OS	Median	All	0.154	0.671	.006	6	view →
BLCA	DFS	Median	All	1.000	0.326	.030	4	view →
GBM	DFS	Median	All	0.031	0.243	<.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LRRC57–ESCA (OS)

Open the ESCA breakdown →